HK1077592A1 - 改進型fc融合蛋白質 - Google Patents

改進型fc融合蛋白質

Info

Publication number
HK1077592A1
HK1077592A1 HK06100143.0A HK06100143A HK1077592A1 HK 1077592 A1 HK1077592 A1 HK 1077592A1 HK 06100143 A HK06100143 A HK 06100143A HK 1077592 A1 HK1077592 A1 HK 1077592A1
Authority
HK
Hong Kong
Prior art keywords
domain
fusion proteins
improved
ligand
receptor
Prior art date
Application number
HK06100143.0A
Other languages
English (en)
Inventor
Henning Walczak
Original Assignee
Apogenix Gmbh
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh, Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts filed Critical Apogenix Gmbh
Publication of HK1077592A1 publication Critical patent/HK1077592A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
HK06100143.0A 2003-03-26 2006-01-04 改進型fc融合蛋白質 HK1077592A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006949 2003-03-26
PCT/EP2004/003239 WO2004085478A2 (en) 2003-03-26 2004-03-26 Improved fc fusion proteins

Publications (1)

Publication Number Publication Date
HK1077592A1 true HK1077592A1 (zh) 2006-02-17

Family

ID=33040920

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100143.0A HK1077592A1 (zh) 2003-03-26 2006-01-04 改進型fc融合蛋白質

Country Status (15)

Country Link
US (2) US8007813B2 (zh)
EP (2) EP1606318B1 (zh)
JP (2) JP4741464B2 (zh)
AT (1) ATE438662T1 (zh)
AU (2) AU2004224123A1 (zh)
CA (2) CA2520138C (zh)
CY (1) CY1109536T1 (zh)
DE (1) DE602004022390D1 (zh)
DK (1) DK1606318T3 (zh)
ES (1) ES2327409T3 (zh)
HK (1) HK1077592A1 (zh)
PL (1) PL1606318T3 (zh)
PT (1) PT1606318E (zh)
SI (1) SI1606318T1 (zh)
WO (2) WO2004085478A2 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
JP5964538B2 (ja) * 2005-02-03 2016-08-03 コーダ セラピューティクス， インコーポレイテッド 抗コネキシン化合物およびそれらの使用
JP2009505989A (ja) 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＶＥＧＦによって活性化されるＦａｓリガンド
KR101866623B1 (ko) * 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP1969009A4 (en) * 2005-12-20 2009-07-22 Arana Therapeutics Ltd CHIMERIC ANTIBODIES AT PRIMATE PARTIAL BINDING REGIONS OF THE NEW WORLD
AU2007211829C9 (en) 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2007131652A1 (de) * 2006-05-17 2007-11-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum auffinden von antiatherosklerotischen substanzen
PL2101877T3 (pl) * 2006-12-28 2013-11-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
US8592557B2 (en) 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CA2790245C (en) 2010-02-19 2018-10-09 Universite De Liege A polynucleotide for use in treatment of influenza a virus induced diseases, encoding modified mx protein, said modified mx protein, and a transgenic animal expressing gene encoding modified mx protein
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CN104411718B (zh) * 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
AU2013291981B2 (en) 2012-07-18 2017-05-04 Apogenix Ag Inhibitors of the CD95 signaling pathway for treatment of MDS
EP2875045B1 (en) * 2012-07-18 2018-03-28 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
EP3131922B1 (en) * 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
MX2017014140A (es) 2015-05-04 2018-03-15 Apogenix Ag Proteinas agonistas receptoras cd40 de cadena simple.
WO2017068180A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
EP3946437A1 (en) 2019-03-29 2022-02-09 Myst Therapeutics, LLC Ex vivo methods for producing a t cell therapeutic and related compositions and methods
AU2020391231A1 (en) 2019-11-27 2022-07-14 Myst Therapeutics, Llc Method of producing tumor-reactive T cell composition using modulatory agents
IL295990A (en) 2020-02-27 2022-11-01 Myst Therapeutics Llc Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6306395B1 (en) 1996-05-02 2001-10-23 Mochida Pharmaceutical Co., Ltd. Fas antigen derivatives
JP4339405B2 (ja) * 1996-10-31 2009-10-07 持田製薬株式会社 予防・治療剤
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
ZA981478B (en) 1997-02-21 1998-08-24 Vlaams Interuniv Inst Biotech Use of interleukin-15
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
CA2324517A1 (en) 1998-03-30 1999-10-07 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DE19959049A1 (de) 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10122140A1 (de) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
AU2002309647C1 (en) * 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DE10160248A1 (de) 2001-12-07 2003-06-26 Alexander Cherkasky Fusionsproteinen enthaltend Fc-Regionen

Also Published As

Publication number Publication date
PT1606318E (pt) 2009-11-10
PL1606318T3 (pl) 2010-01-29
SI1606318T1 (sl) 2009-12-31
AU2004224122A1 (en) 2004-10-07
EP1606319A2 (en) 2005-12-21
DK1606318T3 (da) 2009-11-02
CA2520138A1 (en) 2004-10-07
JP2007533595A (ja) 2007-11-22
WO2004085479A3 (en) 2004-11-25
JP4741464B2 (ja) 2011-08-03
WO2004085479A2 (en) 2004-10-07
EP1606318B1 (en) 2009-08-05
CA2520254A1 (en) 2004-10-07
ES2327409T3 (es) 2009-10-29
DE602004022390D1 (de) 2009-09-17
EP1606318A2 (en) 2005-12-21
CY1109536T1 (el) 2014-08-13
AU2004224123A1 (en) 2004-10-07
WO2004085478A3 (en) 2005-01-06
CA2520138C (en) 2017-05-23
JP2007524365A (ja) 2007-08-30
US20070269449A1 (en) 2007-11-22
WO2004085478A2 (en) 2004-10-07
US20110305697A1 (en) 2011-12-15
ATE438662T1 (de) 2009-08-15
US8007813B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
HK1077592A1 (zh) 改進型fc融合蛋白質
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
RS51318B (sr) Varijante imunoglobulina i njihova upotreba
DE69918946D1 (de) Rezeptoren für il-18
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
WO2003034903A3 (en) Psma antibodies and protein multimers
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO2011003I1 (no) Dimensk fusjonsprotein bestående av de ligandbindende cfomener av de ekstacellulære deler av human type I interieukm-1 reseptor (IL-1R1) og IL-1 reseptor hjelpeprotein bundet (IL-I-RAcP) bundet i tinje til Fc-delen av humant IgG
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
BR0314092A (pt) proteìnas de fusão de transferrina modificadas
DK1392359T4 (da) Specifikke bindingsproteiner og deres anvendelser.
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2003068977A3 (de) Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
ATE388227T1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
DK1572931T3 (da) Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet
WO2003027239A3 (en) Melanin-concentrating hormone receptor antagonist binding protein
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
ATE466076T1 (de) Gewebe transglutaminase